elder law weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of elder law weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Enzon Pharmaceuticals, Inc.
FDA accepts Onco TCS new drug application
June 23rd, 2004
Enzon Pharmaceuticals, Inc., (ENZN) and Inex Pharmaceuticals Corporation (INEX, IEX) announced that the new drug application (NDA) for Onco TCS (vincristine sulfate liposomes injection) has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted a Standard Review designation. Based on this designation, the FDA has established a target date of January 15, 2005, for completion of review of the Onco TCS NDA. The NDA is seeking marketing approval for Onco TCS as a single-agent treatment for patients with relapsed aggressive non-Hodgkin lymphoma (NHL) previously treated with at least two combination chemotherapy regimens. ...
Source: elder law weekly (2004-06-23)
|
